Suboptimal use of antidepressants in the treatment of depression

CNS Drugs

Volumn 13, Issue 5, 2000, Pages 365-383

  Donoghue, John ^a,c   Taylor, David M ^b  

^a PCS Health   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c PCS Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

DEPRESSION; DRUG EFFICACY; DRUG USE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0034014297     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013050-00006     Document Type: Review

References (108)

1. 1. Donoghue JM. Sub-optimal use of tricyclic antidepressants in primary care [editorial]. Acta Psychiatr Scand 1998; 98: 429-31
2. 2. Weiller E, Lecrubier Y, Boyer P. Antidepressant use in general practice. Therapie 1996; 51: 429-30
3. 3. Klerman GL, Weissman MM. The course, morbidity, and costs of depression. Arch Gen Psychiatry 1992; 49: 831-4
4. 4. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989; 262: 914-9
5. 5. Hays RD, Wells KB, Sherbourne CD, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995; 52: 11-9
6. 6. Simon GE, VonKorff M, Barlow W. Health care costs of primary care patients with recognised depression. Arch Gen Psychiatry 1995; 52: 850-6
7. 7. Kind P, Sorensen J. The costs of depression, Int Clin Psychopharmacology 1993; 7: 191-5
8. 8. Brugha TS. Depression undertreatment: lost cohorts, lost opportunities? Psycholog Med 1995; 25: 3-6
9. 9. Pharmacotherapy of depressive disorders: a consensus statement. WHO Mental Health Collaborating Centres. J Affect Disord 1989; 17 (2): 197-8
10. 10. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992; 305: 1198-202
11. 11. Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants. J Psychopharmacol 1993; 7: 19-23
12. 12. Clinical Resource and Audit Group. Depressive illness: a critical review of current practice and the way ahead. Consensus statement. Edinburgh: The Scottish Office, National Health Service in Scotland, 1993
13. 13. Depression Guideline Panel, Agency for Health Care Policy Research Treatment of Major Depression. Clinical practice guideline. No. 5, Vol. 2. Rockville (MD): US Department of Health and Human Services, 1993 (AHCPR Publication No. 93-0550, 1993. 20)
14. 14. The treatment of depression in primary care: which treatments are effective in the management of depression in primary care? Eff Health Care 1993; 5: 1-12
15. 15. Selecting an antidepressant. MeReC Bulletin 1995; 6 (1): 1-4
16. 16. Karasu TB, Docherty JP, Gelenberg A, et al. Practice guideline for major depressive disorder in adults. In: Practice guidelines. Washington, DC: American Psychiatric Association, 1996: 83-127
17. 17. Crismon ML, Trivedi M, Pigott TA, et al. The Texas medication algorithm project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry 1999; 60: 142-56
18. 18. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-7
19. 19. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8: 238-49
20. 20. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53
21. 21. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997; 170: 120-7
22. 22. Kendrick T. Prescribing antidepressants in general practice: watchful waiting for minor depression, full dose treatment for major depression. BMJ 1996; 313: 829-30
23. 23. Paykel ES, Hollyman JA, Freeling P, et al. Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. J Affect Disord 1988; 14: 83-95
24. 24. Thompson C, Thompson CM. The prescribing of antidepressants in general practice: II. A placebo-controlled trial of low-dose dothiepin. Hum Psychopharmacol 1989; 4: 191-204
25. 25. Tyrer P, Murphy S, Kingdon D, et al. The Nottingham study of neurotic disorder: comparison of drug and psychological treatments. Lancet 1988; 1: 235-40
26. 26. Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants: meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999; 174: 297-303
27. 27. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995; 4: 261-77
28. 28. Maj M, Vietro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery of an episode of major depression: a prospective study. Am J Psychiatry 1992; 149: 795-800
29. 29. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998; 55: 1128-32
30. 30. Johnson DAW. Treatment of depression in general practice. BMJ 1973; 1: 18-20
31. 31. Kotin J, Post RM, Goodwin FK. Drug treatment of depressed patients referred for hospitalisation. Am J Psychiatry 1973; 130: 1139-41
32. 32. Johnson DAW. A study of the use of antidepressant medication in general practice. Br J Psychiatry 1974; 125: 186-92
33. 33. Johnson DAW. Depression: treatment compliance in general practice. Acta Psychiatr Scand 1981; 63 Suppl. 290: 447-53
34. 34. Keller MB, Klerman GL, Lavori PW, et al. Treatment received by depressed patients. J Am Med Assoc 1982; 248: 1848-55
35. 35. Jick H, Dinan BJ, Hunter JW, et al. Tricyclic antidepressants and convulsions. J Clin Psychopharmacol 1983; 3: 182-5
36. 36. Jones L, Simpson D, Brown AC, et al. Prescribing psychotropic drugs in general practice: three year study. BMJ 1984; 289: 1045-8
37. 37. Pollock BG, Perel JM. Tricyclic antidepressants: contemporary issues for therapeutic practice. Can J Psychiatry 1989; 34: 609-17
38. 38. Keller MB, Lavori PW, Klerman GL, et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986; 43: 458-66
39. 39. Thompson C, Thompson CM. The prescription of antidepressants in general practice: I. A critical review. Hum Psychopharmacol 1989; 4: 91-102
40. 40. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a medicaid population. J Clin Psychiatry 1990; 51 Suppl. 6: 60-9
41. 41. Katon W, VonKorff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30: 67-76
42. 42. Simon GE, VonKorff M, Wagner EH, et al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993; 15: 399-408
43. 43. Rosholm J-U, Hallas J, Gram LF. Outpatient utilisation of antidepressants: a prescription database analysis. J Affect Disord 1993; 27: 21-8
44. 44. Rosholm JU, Gram LF, Damsbo N, et al. Antidepressant treatment in general practice - an interview study. Scand J Prim Care 1995; 13: 281-6
45. 45. Munizza C, Tibaldi G, Bollini P, et al. Prescription pattern of antidepressants in out-patient psychiatric practice. Psychologic Med 1995; 25: 771-8
46. 46. Bingefors K, Isacson D, von Knorring L. Antidepressant dose patterns in Swedish clinical practice. Int Clin Psychopharmacol 1997; 12 (5): 283-90
47. 47. Donoghue JM, Tylee A, Wildgust HJ. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ 1996; 313: 861-2
48. 48. Matthews K, Eagles JM, Matthews CA. The use of antidepressant drugs in general practice: a questionnaire survey. Euro J Clin Pharmacol 1993; 45: 205-10
49. 49. Kerr MP. Antidepressant prescribing: a comparison between general practitioners and psychistrists. Br J Gen Pract 1994; 44: 275-6
50. 50. Thomson RJ. Antidepressant prescribing among referrals to a community mental health unit in New Zealand. Psychiatr Bull 1994; 18:461-2
51. 51. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
52. 52. Donoghue JM. The prescribing of antidepressants in general practice: the use of PACT data (brief report). Postgrad Med J 1994; 70 Suppl. 2: S23-S24
53. 53. Wells KB, Katon W, Rogers B, et al. Use of minor tranquillisers and antidepressant medications by depressed outpatients: results from the Medical Outcomes Study. Am J Psychiatry 1994; 151:694-700
54. 54. Arpino C, Da Cas R, Donini G, et al. The use and misuse of antidepressant drugs in a random sample of the population of Rome, Italy. Acta Psychiatr Scand 1995; 92: 7-9
55. 55. Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the United Kingdom. Br J Psychiatry 1996; 168: 164-8
56. 56. MacDonald TM, McMahon AD, Reid IC, et al. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. BMJ 1996; 313: 860-1
57. 57. World Health Organization. International classification of diseases. 10th ed. Geneva: World Health Organization, 1992
58. 58. Rouillon F, Blachier C, Dreyfus JP, et al. Etude pharmacoepidemiologique de la consommation des antidepresseurs en population generale L'encephale Sp 1996; 1: 39-48
59. 59. Gregor KJ, Hylan TR, van Dijk PCM, et al. Outpatient antidepressant utilisation in a Dutch sick fund. Am J Manage Care 1998; 4: 1150-60
60. 60. Isometsa E, Seppala I, Henriksson M, et al. Inadequate dosaging in general practice of tricyclic vs. other antidepressants for depression. Acta Psychiatr Scand 1998; 98; 451-4
61. 61. Donoghue J, Katona C, Tylee A. The treatment of depression: antidepressant prescribing for elderly patients in primary care. J Pharm 1998; 260: 500-2
62. 62. Dunn RL, Donoghue JM, Ozminkowski RJ, et al. Longitudinal patterns of antidepressant prescribing in primary cure in the UK: comparison with treatment guidelines. J Psychopharmacol 1999; 13 (2): 136-43
63. 63. Donoghue JM. Selective serotonin re-uptake inhibitor use in primary care: a five year naturalistic study. Clin Drug Invest 1998 Dec; 16 (6): 453-62
64. 64. Tylee A, Gastpar M, Lepine J-P, et al. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability, and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999; 14 (3): 139-51
65. 65. Keller MB, Klerman GL, Lavori PW, et al. The persistent risk of chronicity in recurrent episodes of non-bipolar major depressive disorder: a prospective follow-up. Am J Psychiatry 1986; 143: 24-8
66. 66. Kiloh LG, Andrews G, Neilson M. The long-term outcome of depressive illness. Br J Psychiatry 1988; 153: 752-7
67. 67. Goethe JW, Szarek BL, Cook WL. A comparison of adequately vs. Inadequately treated depressed patients. J Nerv Ment Dis 1988; 176: 465-70
68. 68. Scott J. Chronic depression. Br J Psychiatry 1988; 153: 287-97
69. 69. Rutz W, Walinder J, Eberhard G, et al. An educational programme on depressive disorders for general practitioners in Gotland: Background and evaluation. Acta Psychiatr Scand 1989; 79: 19-26
70. 70. Bacani-Oropilla T, Lippman SB. Chronic depression: issues in long-term management. Postgrad Med 1989; 85: 171-5
71. 71. Frank E, Kupfer DJ, Perel JM, et al. Three year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093-9
72. 72. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH collaborative study group comparing lithium carbonate, imipramone, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41: 1096-104
73. 73. Thase ME. Relapse and recurrence in umipolar major depression: short-term and long-term approaches. J Clin Psychiatry 1990; 51 Suppl.: 51-7
74. 74. Scott J, Eccleston D. Prediction, treatment and prognosis of chronic primary major depression. Int Clin Psychopharmacol 1991; 6 Suppl. 1: 41-9
75. 75. Brugha TS, Bebbington PE, MacCarthy B, et al. Antidepressants may not assist recovery in practice: a naturalistic prospective survey. Acta Psychiatr Scand 1992; 86: 5-11
76. 76. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49 (10): 761-8
77. 77. Shea MT, Elkin I, Imber SD, et al. Course of depressive symptoms over follow-up. Arch Gen Psychiatry 1992; 49: 782-7
78. 78. Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993; 27: 139-45
79. 79. Isacsson G, Holmgren P, Wassermen D, et al. Use of antidepressants among people committing suicide in Sweden. Br Med J 1994; 308: 506-9
80. 80. Simon GE, Lin EHB, Katon W, et al. Outcomes of 'inadequate' antidepressant treatment. J Gen Intern Med 1995; 10: 663-70
81. 81. Schulberg HC, Block MR, Madonia MJ, et al. Treating major depression in primary care practice. Eight month clinical outcomes. Arch Gen Psychiatry 1996; 53: 913-9
82. 82. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
83. 83. Lave JR, Frank RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998; 55: 645-51
84. 84. Ali IM. Long-term treatment with antidepressants in primary care. Psychiatr Bull 1998; 22: 15-9
85. 85. Fish D. What is an effective dose [letter]? BMJ 1997; 314: 826
86. 86. Moore MV. More on what is an effective dose [letter]. BMJ 1997; 314: 826
87. 87. Tan RS. Low dose tricyclic antidepressants are effective in treating major depression [letter]. BMJ 1997; 314: 827
88. 88. Dodd GK, Berti C. A critical appraisal of a naturalistic study to support cost effective prescribing patterns of selective serotonin reuptake inhibitors in primary care. J Serotonin Res 1997; 3: 169-72
89. 89. Donoghue JM. Response to: a critical appraisal of a naturalistic study to support cost effective prescribing patterns of selective serotonin reuptake inhibitors in primary care. J Serotonin Res 1997; 4: 233-7
90. 90. Hotopf M, Lewis G, Normand C. Putting trials on trial - the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health 1997; 51: 354-8
91. 91. Freeman HL, O'Hanlon JF. Acute and subacute effects of antidepressants on performance. J Drug Dev Clin Pract 1995; 7: 7-20
92. 92. Ray WA. Psychotropic drugs and injuries among the elderly: a review. J Clin Psychopharmacol 1992; 12: 386-96
93. 93. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ 1995; 310: 221-4
94. 94. Detnyttenaere K. Compliance during treatment with antidepressants. J Affect Disord 1997; 43: 27-39
95. 95. Freemantle N, House A, Mason J, et al. Economics of treatment of depression [letter]. Br J Psychiatry 1995; 166: 397
96. 96. Hotopf M, Lewis G, Normand C. Are SSRIs a cost effective alternative to tricyclics? Br J Psychiatry 1996; 168: 404-9
97. 97. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
98. 98. Le Pen C, Levy E, Ravily J, et al. The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs tricyclics. J Affect Disord 1994; 31: 1-18
99. 99. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organisation. Clin Ther 1994; 16: 715-30
100. 100. Stewart A. Antidepressant pharmacotherapy: cost comparison of SSRIs and TCAs. BMJ Economics 1994; 7: 67-79
101. 101. Lapierre Y, Bentkover J, Schainbaum S, et al. Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Can J Psychiatry 1995; 40: 370-7
102. 102. Simon G, Wagner E, VonKorff M. Cost-effectiveness comparisons using 'real world' randomised trials: the case of new antidepressant drugs. J Clin Epidemiol 1995; 48: 363-73
103. 103. Skaer TL, Sclar DA, Robison LM, et al. Economic evaluation of amitriptyline, desipramine, nortriptyline and sertraline in the management of patients with depression. Curr Ther Res 1995; 56: 556-67
104. 104. Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996; 38: 97-111
105. 105. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. J Am Med Assoc 1996; 275: 1897-902
106. 106. Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Manage Care 1996; 2: 1239-46
107. 107. Donoghue JM. Costs of treating depression: policy should be evidence-based [commentary]. In: Maj M, Sartorius N, editors. Depressive disorders. Vol. 1. Chichester: John Wiley & Sons Ltd, 1999: 459-61 (Evidence and Experience in Psychiatry Series, World Psychiatric Association)
108. 108. Rosenbaum JF, Hylan TR. Costs of depressive disorders: a review. In: Maj M, Sartorius N, editors. Depressive disorders. Vol. 1. Chichester: John Wiley & Sons Ltd, 1999: 401-49 (Evidence and Experience in Psychiatry Series, World Psychiatric Association)